NFκB-Luc/EF1α-mCherry Reporter Cell Line - HepG2

The HepG2 cell line, derived from human hepatocellular carcinoma tissue, remains one of the most reliable models for studying human liver function, drug metabolism, and toxicology due to its retention of hepatocyte-like characteristics. The NFkB-Luc/EF1α-mCherry Reporter Cell Line - HepG2 is a genetically engineered version of this model designed for the sensitive detection of NF-kappa B (NF-κB) pathway activity. This specific line features a dual-reporter system: the firefly luciferase gene is controlled by a synthetic promoter containing multiple NF-κB response elements, while the mCherry fluorescent protein is constitutively expressed under the EF1α promoter. This configuration allows for the quantitative measurement of transcriptional activation through bioluminescence, alongside a stable red fluorescent signal that serves as an internal control for cell density, viability, and normalization across different experimental conditions.

This reporter system is particularly effective for high-throughput screening of anti-inflammatory drugs and the assessment of liver-specific inflammatory responses. By monitoring luciferase expression, researchers can accurately gauge the activation of the NF-κB pathway in response to external stimuli like TNF-alpha or interleukin-1 beta, which are critical in the study of chronic liver diseases and immune regulation. The integration of mCherry provides a distinct advantage by allowing for real-time monitoring of cell health, ensuring that any observed reduction in luciferase activity is a result of pathway inhibition rather than non-specific drug-induced cell death. Consequently, this cell line is a powerful tool for investigating the molecular mechanisms of liver inflammation, exploring the effects of various cytokines, and developing therapeutic interventions for conditions such as hepatitis and non-alcoholic fatty liver disease. The stability and reproducibility of the reporter signals make it ideal for long-term assays and complex drug toxicity evaluations in the pharmaceutical industry.